Striant is one of several testosterone therapies subject to label revisions due to a possible link with an increased risk of heart and stroke in certain men. Thousands of low-T therapy users are now pursuing testosterone lawsuits for cardiovascular side effects allegedly related to the use of these medications.

Striant Lawsuit Reviews

The nationwide law firm of Bernstein Liebhard LLP is now offering free, no-obligation legal reviews to men who may have suffered a heart attack, stroke, deep vein thrombosis, or pulmonary embolism while using prescription low-T therapy. If you are interested in filing a Striant lawsuit, please contact our legal staff by calling (888) 994-5118.

What is Striant?

Approved in 2004, Striant (testosterone buccal) is used to treat men with hypogonadism (low testosterone levels) that is associated with some underlying medical condition, such as the side effects of chemotherapy or certain pituitary disorders. Striant tablets were designed to adhere to the gum or inner cheek, where the drug slowly delivers a controlled amount of testosterone via the mucous membranes of the mouth.

The safety and efficacy of Striant in men with “age-related hypogonadism” have not been established.

The Testosterone Controversy

In recent years, the off-label use of low-T therapy in men who suffer from age-related drops in testosterone has become controversial. In a March 2015 Safety Communication, the U.S. Food & Drug Administration (FDA) noted the use of testosterone replacement therapy has increased significantly, from 1.3 million patients in 2009 to 2.3 million patients in 2013 receiving a prescription for a testosterone product. The FDA expressed concern that testosterone is being used extensively in men who are experiencing low testosterone related to aging. The agency ordered the labels of all prescription testosterone treatments to state clearly that the medications have not been proven safe and effective in treating age-related hypogonadism. Read More

FDA Testosterone Warnings

  • January 2014: The FDA announced it was reviewing the safety of all low-T therapies amid concerns that the drugs might increase the risk of heart attacks and strokes in certain men.
  • June 2014: The FDA directed manufacturers of prescription testosterone treatments to add new blood clot warnings to their product labels, following report of venous blood clots, including pulmonary embolism and deep vein thrombosis, occurring in men who were treated with the drugs. Read More
  • March 2015: The FDA concluded the review announced in January 2015, and orders low-T manufacturers to add new warnings to their product labels regarding a possible association with heart attacks and strokes.

Studies Point to Low-T Heart Risks

  • November 2013: A scientific paper published in JAMA suggests that use of prescription testosterone treatments is associated with a 25.7% risk of cardiovascular side effects, compared to 19.9% for men who were not on the drugs.
  • January 2014: A study publishes in PLoS One found that men over 65 were twice as likely to have a heart attack if they used low-T treatments, while men under 65 with pre-existing heart disease were three times as likely to have a heart attack if they used the drugs.

Legal Help for Those Harmed by Natesto

If you or a man you care about suffered a heart attack, stroke or dangerous blood clot while using Striant, now is the time to ensure your legal rights are protected. To learn more about the growing testosterone litigation, please call (888) 994-5118.

Last Modified: February 23, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content